Physician profile
Gifty J Appiah
NPI 1730345745
$1,159.55
in general payments reported to CMS, 2019-2025
13 companies · $284 in 2025
The $284 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $131 · 2022: $13.04 · 2023: $54.00 · 2024: $677 · 2025: $284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $910 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $909.58 |
| Education | $105.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $322.87 | 2024-2025 | Austedo Xr, Austedo Xr |
| Neurocrine Biosciences, INC. | $263.99 | 2024-2025 | Ingrezza |
| Urovant Sciences INC | $131.43 | 2021 | |
| Idorsia Pharmaceuticals US INC | $108.60 | 2023-2024 | Quviviq |
| Lilly USA, LLC | $53.89 | 2024 | Zepbound |
| Otsuka America Pharmaceutical, INC. | $47.34 | 2024 | Rexulti |
| Acadia Pharmaceuticals INC | $47.00 | 2022-2025 | Nuplazid |
| Medtronic, INC. | $43.54 | 2024 | Linq II |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.36 | 2023 | Xifaxan, Trulance |
| Emd Serono, INC. | $32.10 | 2024 | Serostim |
| Vanda Pharmaceuticals INC. | $30.90 | 2025 | Fanapt |
| Sk Life Science, INC. | $26.66 | 2025 | Xcopri |
| Pfizer INC. | $15.87 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gifty Appiah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.